Drug Profile
Research programme: immune therapeutics - Eisai Andover innovative Medicines (AiM) Institute
Alternative Names: AiM institute immune therapeuticsLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Eisai Andover Innovative Medicines Institute
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain disorders; Cancer; Immunological disorders
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Brain-disorders in USA
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2020 No recent reports of development identified for research development in Immunological-disorders in USA